{"id":"mrna-1345","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL529626","moleculeType":"Small molecule","molecularWeight":"617.79"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The vaccine works by encoding for a piece of the SARS-CoV-2 spike protein, which is then produced by the host cells and recognized by the immune system as foreign, triggering an immune response. This immune response helps to prevent future infections by providing immunity against the SARS-CoV-2 virus.","oneSentence":"mRNA-1345 is an mRNA-based vaccine designed to prevent COVID-19 infection by inducing an immune response against the SARS-CoV-2 virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:10.818Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 disease"}]},"trialDetails":[{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT06143046","phase":"PHASE2","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-11-15","conditions":"Respiratory Syncytial Virus","enrollment":360},{"nctId":"NCT07117487","phase":"PHASE3","title":"A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2025-08-05","conditions":"Respiratory Syncytial Virus","enrollment":507},{"nctId":"NCT05330975","phase":"PHASE3","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-04-01","conditions":"Respiratory Syncytial Virus","enrollment":3317},{"nctId":"NCT05606965","phase":"PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-02","conditions":"Influenza","enrollment":172},{"nctId":"NCT05743881","phase":"PHASE1","title":"A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-02-15","conditions":"Respiratory Syncytial Virus, Human Metapneumovirus","enrollment":186},{"nctId":"NCT05127434","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-11-17","conditions":"Respiratory Syncytial Virus","enrollment":36814},{"nctId":"NCT06067230","phase":"PHASE3","title":"A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-10-06","conditions":"Respiratory Syncytial Virus","enrollment":1153},{"nctId":"NCT06060457","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-09-25","conditions":"Respiratory Syncytial Virus","enrollment":1900},{"nctId":"NCT06097299","phase":"PHASE2","title":"A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-10-24","conditions":"Respiratory Syncytial Virus","enrollment":346},{"nctId":"NCT05572658","phase":"","title":"Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-09-15","conditions":"Respiratory Syncytial Virus","enrollment":10994},{"nctId":"NCT04528719","phase":"PHASE1","title":"A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2020-09-30","conditions":"Respiratory Syncytial Virus","enrollment":651},{"nctId":"NCT05585632","phase":"PHASE1","title":"A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-10-14","conditions":"SARS-CoV-2, Influenza, RSV","enrollment":392}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"mRNA-1345","genericName":"mRNA-1345","companyName":"ModernaTX, Inc.","companyId":"modernatx-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"mRNA-1345 is an mRNA-based vaccine designed to prevent COVID-19 infection by inducing an immune response against the SARS-CoV-2 virus. Used for Prevention of COVID-19 disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}